CSI Market
Sign In | Register

Amylyx Pharmaceuticals Inc (AMLX) Annual Cash Flow Statement

Annual · GAAP · USD millions
Access AMLX quarterly Cash Flow →
This cash flow overview for Amylyx Pharmaceuticals Inc spans from to Dec 31 2025, illustrating how cash generation and usage have shifted across recent reporting periods.
View historic periods: Download as CSV:
Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.
Annual Report, GAAP in USD millions
ITEM 		(Dec 31 2025)
12 Months 		(Dec 31 2024) (Dec 31 2023) (Dec 31 2022)
Operating Activities
Income-144.74
Depreciation & amortization0.53
Amortization of Other Assets0.00
Extraordinary Item, Gain (Loss), Insurance Assets, Accretion Expense0.00
Asset Impairment Charges0.00
Provision For Loan Losses Expensed0.00
Increase (Decrease) in Inventories0.00
R & D, Environmental and Other Expense0.00
Gain (Loss) on Disposition of Assets0.00
Share-based Compensation27.65
Income (Loss) from Equity Method Investments0.00
Financial Instruments and Foreign Currency Transaction0.00
Change In Fair Value Of Convertible Notes-
Increase Decrease In Operating Lease Right Of Use Assets1.73
Increase Decrease In Accrued Expenses And Deferred Rent-
Initial Public Offering Costs Included In Accounts Payable And Accrued Expenses-
Public Offering Costs Included In Accounts Payable And Accrued Expenses-
Deferred Offering Costs Included In Accounts Payable And Accrued Expenses-
Conversion Of Convertible Notes And Accrued Interest Into Redeemable Convertible Preferred Stock-
Cost Of Sales Inventory Impairment And Loss On Firm Purchase Commitments-
Charge For In Process Research And Development Milestones-1.16
Income taxes0.00
Unrealized Gain (Loss) on Investments0.00
Accounts Receivable0.38
Increase (Decrease) in Accounts Payable0.58
Increase (Decrease) in Accrued Liabilities-6.60
Deferred Revenue and Customer Advances and Deposits0.00
Increase (Decrease) in Prepaid Expense and Other Assets5.96
Other Working Capital0.00
Other Noncash Income (Expense)-0.17
Other net0.00
Payments for (Proceeds from) Other Operating Activities-7.50
Discontinued operations0.00
Net Cash flow from Operating Activities-123.34
Investing Activities
Capital Expenditures-0.14
Sale of Capital Items0.00
Proceeds from Sale and Maturity of Marketable Securities246.00
Short-term Investments Acq.0.00
Real Estate Investments0.00
Milestone Payments Related To In Process Research And Development-
Restricted Cash and Investments Increase (Decrease)0.00
Payments for (Proceeds from) Loans0.00
Payments for (Proceeds from) Deposits0.00
Payments to Acquire Investments-231.82
Payments for (Proceeds from) Federal Reserve and FHLB0.00
Acquisition Net of Cash Acquired0.00
Interest in Subsidiaries and Affiliates0.00
Sale of businesses0.00
Accounts payable0.00
Receivables0.00
Payments for (Proceeds from) Other Investing Activities0.00
Other Net0.00
Discontinued operations0.00
Net Cash Flow from Investing Activities14.04
Financing Activities
Short-term debt Net0.00
Other borrowing transactions0.00
Long-term debt - borrowings256.31
Long-term debt - repayments0.00
Federal Home Loan Bank and Federal Funds0.00
Issuances / -repurchases of Comm. Stock0.00
Partnership and Parent Transactions0.00
Issuances / -repurchases of Pref. Stock0.00
Deposits, Annuities, Contract Holders Funds0.00
Other financing activities net0.00
Other net-74.76
Forgiveness Of P P P Loan-
Initial Public Offering Cost Paid During The Quarter-
Proceeds From Issuance Of Convertible Notes Related Parties-
Issuance Costs Related To Conversion Of Convertible Notes-
Payment Of Deferred Offering Costs-
Proceeds From Repayments Of Paycheck Protection Program Loan-
Issuance Costs Related To Issuance Of Series Redeemable Convertible Preferred Stock-
Initial Public Offering Cost Paid-
Follow On Offering Costs Paid-
Withholding Taxes Paid On Stock Based Awards-3.36
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations78.84
Taxes Withheld On Stock Based Awards Included In Accrued Expenses-
Purchases Of Property And Equipment Included In Accounts Payable-
Payments of Dividends, Preferred Stock and Preference Stock0.00
Dividends paid0.00
Net Cash Flow from Financing Activities257.03
Effect of exchange rate on cash flow1.07
Discontinued operations0.00
Free Cash Flow-123.48
Total Cash Flow148.80
4 historic quarters locked

Sign in to unlock the full Amylyx Pharmaceuticals Inc cash flow history.

Sign In Create Free Account

About Amylyx Pharmaceuticals Inc Annual Cash Flow Statement

What this statement shows

This page presents issuer-reported cash flow data, including operating, investing, financing, net, and free cash flow, as disclosed in SEC 10-K filings and normalized by CSIMarket.

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings - XBRL extraction - normalization in the CSIMarket.com database.
  • Accession: 0001193125-26-086645

Figures are derived from filed reports and may be restated. Historical data is subject to revision.

Untitled Document 





                    


    



  Get the full CSIMarket dataset:
  Subscribe
  API
  License